Tech Company Financing Transactions
Allay Therapeutics Funding Round
On 6/5/2025, Allay Therapeutics secured $57.5 million in Series D investment from ClavystBio, Lightstone Ventures and Arboretum Ventures.
Transaction Overview
Company Name
Announced On
6/5/2025
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$57,500,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds to supports its Phase 2b registration trial evaluating ATX101 for the treatment of post-surgical pain following total knee replacement (TKA) surgery and advances its ultra-sustained platform of products for other unmet needs after painful surgeries.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4040 Campbell Ave. 110
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Undisclosed
Website
Email Address
Overview
One global team united behind a mission to transform pain management. Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. We believe an era of stalled innovation for pain management is over.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Adam Gridley
Chief Technical Officer
Patrick Ruane
General Manager
Koon Teu
Vice President
Melinda Morrell
VP - Product Management
Cyndi Lee
VP - Regulatory Affairs
Sharon Hall
VP - Regulatory Affairs
Hans Schulz
Browse more venture capital transactions:
Prev: 6/5/2025: Payall venture capital transaction
Next: 6/5/2025: Signify Bio venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs